ARQ 197 and Erlotinib
Phase 1Completed 1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-small-cell Lung Cancer
Conditions
Non-small-cell Lung Cancer
Trial Timeline
Feb 1, 2010 → Sep 1, 2011
NCT ID
NCT01069757About ARQ 197 and Erlotinib
ARQ 197 and Erlotinib is a phase 1 stage product being developed by Kyowa Kirin for Non-small-cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01069757. Target conditions include Non-small-cell Lung Cancer.
What happened to similar drugs?
7 of 20 similar drugs in Non-small-cell Lung Cancer were approved
Approved (7) Terminated (6) Active (9)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01251796 | Phase 1 | Completed |
| NCT01069757 | Phase 1 | Completed |
Competing Products
20 competing products in Non-small-cell Lung Cancer